Deciphering downstream receptor signaling

被引:0
|
作者
Filizola, Marta [1 ]
Javitch, Jonathan A. [2 ,3 ,4 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA
[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Mol Pharmacol & Therapeut, New York, NY USA
[4] New York State Psychiat Inst & Hosp, Div Mol Therapeut, New York, NY USA
基金
美国国家卫生研究院;
关键词
D O I
10.1126/science.adm8393
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
G protein-coupled receptors (GPCRs) are important cell-surface signaling proteins that are responsive to diverse extracellular stimuli and are key drug targets (1). Understanding how compounds activate GPCRs and modulate their interactions with intracellular proteins such as G proteins and beta-arrestins is crucial for drug discovery because these proteins transduce signals to downstream effectors, triggering biological responses. This includes elucidating the molecular details behind the ability of the drug-GPCR complex to generate a functional response (efficacy) and the concentration of the drug required to produce half-maximal response (potency) (2). Although agonist binding to a GPCR triggers conformational rearrangements throughout the receptor and its transducer (3), the molecular mechanisms that govern ligand efficacy and potency are difficult to ascertain. On page 1378 of this issue, Heydenreich et al. (4) explored how individual amino acids in the prototypical Gs-coupled beta 2-adrenergic receptor "interpret" information encoded in the atoms of its endogenous agonist, adrenaline, to drive its efficacy and potency.
引用
收藏
页码:1357 / 1358
页数:2
相关论文
共 50 条
  • [31] Hierarchy of signaling thresholds downstream of the T cell receptor and the Tec kinase ITK
    Gallagher, Michael P.
    Conley, James M.
    Vangala, Pranitha
    Garber, Manuel
    Reboldi, Andrea
    Berg, Leslie J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (35)
  • [32] In Vitro Effects of Ligand Bias on Primate Mu Opioid Receptor Downstream Signaling
    Zhang, Xiao
    Hutchins, Shaurita D.
    Blough, Bruce E.
    Vallender, Eric J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 15
  • [33] Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies
    Matsumura, Itaru
    Mizuki, Masao
    Kanakura, Yuzuru
    CANCER SCIENCE, 2008, 99 (03) : 479 - 485
  • [34] Insulin receptor endocytosis is independent of signaling pathways downstream of IRS-1
    Boura, HS
    Paz, K
    Voliovitch, H
    Zick, Y
    DIABETOLOGIA, 2000, 43 : A160 - A160
  • [35] Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients
    Miyazaki, Y
    He, H
    Mandarino, LJ
    DeFronzo, RA
    DIABETES, 2003, 52 (08) : 1943 - 1950
  • [36] Plant NLR-triggered immunity: from receptor activation to downstream signaling
    Lolle, Signe
    Stevens, Danielle
    Coaker, Gitta
    CURRENT OPINION IN IMMUNOLOGY, 2020, 62 : 99 - 105
  • [37] Cholesterol dependent ligand binding and downstream signaling of the adenosine A2a receptor
    McGraw, Claire
    Robinson, Anne
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [38] The impact of the epidermal growth factor receptor phosphorylation on downstream signaling in pulmonary adenocarcinomas
    Brcic, L.
    Gygar, E.
    Popper, H.
    VIRCHOWS ARCHIV, 2015, 467 : S41 - S41
  • [39] Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer
    Leu, YW
    Yan, PS
    Fan, MY
    Jin, VX
    Liu, JC
    Curran, EM
    Welshons, WV
    Wei, SH
    Davuluri, RV
    Plass, C
    Nephew, KP
    Huang, THM
    CANCER RESEARCH, 2004, 64 (22) : 8184 - 8192
  • [40] Differential role of phosphodiesterase inhibitors on AMPA receptor trafficking and downstream cyclic nucleotide signaling
    Argyrousi, E.
    Neves-Zaph, S. R.
    Prickaerts, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2018, 28 : S9 - S9